Five Ways a Flat GLP-1 Price Stops Being Flat

A flat price is the right thing to want

Once you accept that a GLP-1 is a standing cost that scales with the dose, the shape of a good price becomes obvious: flat, all-in, and identical at the full maintenance dose as it was at the start. It is not always the lowest sticker on day one; a bare introductory tier somewhere else can undercut it for exactly one month, or exactly two fills. But the number you sign for is the number you are still paying at maintenance, and that is the only comparison that survives a family budget. The true cost of a GLP-1 once the dose climbs makes that case in full.

What this page is for is the next problem. A price can hold at every dose and still not be what you pay. There are five ways that happens, and only one of them is a dose tier.

1. The second charge

The most common. The medication price is flat and genuine — and it is not the whole bill.

The shape worth wanting does exist — FitFlow holds $99 semaglutide and $134 tirzepatide at every dose, and its own JavaScript bundle contains no other price. Mochi Health advertises compounded semaglutide at $99 a month and genuinely holds that rate at every dose, then bills $79 a month for the clinic alongside it. It says so on its own page. No comparison table carries it. The medication price was never the total.

That pattern is not rare; it is closer to the default now that the brand lane has crowded out the compounded one. LifeMD posts $149/month for its program membership — a real, useful number — and a separate line for the medication itself, from $149 for the Wegovy pill up to $349 for a Zepbound vial. Ro does the same with its membership tiers and won't itemize the drug cost at all on its own pricing page. Form Health and Calibrate both post a clean membership fee — $299 and $199 a month — that buys the care team, not the prescription.

None of these are hiding it. But a headline number that is only half the bill is exactly what a family budget cannot spot from the homepage.

2. The price bought with a year

Real, and quoted at a rate you only receive if you commit to twelve months.

Nouri is the clearest version: $120/mo is its headline, but that is $720 paid six months up front, and the true month-to-month rate is $175 — about 46% more. To its credit it publishes all three cadences rather than only the flattering one. Evernow advertises membership "starting at $35/month"; the $35 is the twelve-month prepaid rate, charged as $420 upfront, and the figure you pay if you would like the option of leaving in March is $49. HealthOn is the same variety: "starting at $189" semaglutide and "starting at $290" tirzepatide are both the discounted rate on a full year paid upfront, with no month-to-month number published anywhere.

That structure is common enough to be unremarkable. What is not unremarkable is when the monthly rate does not appear anywhere beside the prepaid one. Before you read any headline as a monthly cost, find the sentence that says how many months it commits you to. If you cannot find one, that is the answer.

3. Two prices for the same plan

Ivologist does scale with dose across its 11-week program, and prices the same plan two different ways on two of its own pages — a weekly figure on the homepage, a monthly figure on the product page. Read the one you are actually about to pay from before you commit.

4. The dose tier above the flat tier

This is the newest, and it is worth knowing because it appeared after the flat-price advice above was written.

Novo Nordisk's own savings terms for Wegovy, read on 2026-08-21, set out the ladder in a single sentence: patients new to the offer pay $199 for each month of 0.25 mg and 0.5 mg, for two monthly fills through December 31, 2026 — and then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg, and $399 per month for Wegovy HD 7.2 mg¹.

Read the enumeration carefully. The $349 rate is flat across five doses, exactly as the budget-proof shape requires. And then there is a sixth dose, approved after that ladder was set, sitting outside it at fifty dollars more.

If you are titrating toward the highest approved dose, the flat price does not follow you all the way up. That is not a trick — it is printed — but it does mean "flat at every dose" is now a claim with an expiry date on it, and any comparison written before the 7.2 mg approval is quietly out of date.

5. The month that is twenty-eight days

The one almost nobody checks, and it is in the same footnote.

"One month defined as 1 box of 4 pens of Wegovy."¹

Four pens, one a week. That is 28 days, not a month.

The arithmetic matters more than it looks:

That is roughly $349 a year more than the sticker implies — one entire extra fill that no annual budget built from "per month" contains.

There is a wrinkle worth knowing if you are on the tablet instead. The same sentence defines a month as one box of four pens and one bottle of 30 tablets¹. Thirty tablets, taken daily, is thirty days — near enough a calendar month. So the 28-day month is a property of the pen, not of the brand, and switching forms changes how many times a year you are billed.

Novo discloses all of it plainly. It is one line in a footnote and it is not buried in legalese. The failure is not concealment; it is that no comparison table in this market carries it, and until today that included ours.

Why the structure matters more than the number

None of this would be worth five sections if cost were a nuisance rather than a reason people stop.

A 2026 qualitative study in JAMA Network Open interviewed 30 people across 15 US states — 19 of them women, mean age 54 — about taking these medications, and analyzed what they said without a predetermined framework. Among the themes participants raised unprompted were that access challenges and cost can be prohibitive, and that these drugs are not a standalone solution but a treatment people expect to stay on².

Put those two together and the pricing structures above stop being paperwork. A program you cannot still afford at the maintenance dose, in month fourteen, is a program that ends — and the weight-regain pattern after stopping is well documented. The structure of the price is therefore a clinical variable, not just a financial one.

What to do with this

The closing question on the parent essay was always the right one to ask: does a "month" mean 28 days or a calendar month? Now there is an answer for at least one manufacturer, and it is 28 days.

So the check is: take the monthly figure, multiply by thirteen, and add any membership fee, twelve times. That number is what a year costs. Compare programs on that, and most of the headline differences in this market rearrange themselves.